Episode
Episode 463: A Novel Approach to Treating MS-Related Depression with Dr. Robert Motl and Kelly
- Podcast
- RealTalk MS
- Published
- Jul 13, 2026
- Duration seconds
- 2226
- Processing state
not_requested- Canonical source
- https://realtalkms.com/463
Actions
POST https://stenobird.com/v1/public/podcasts/realtalk-ms-779631/episodes/episode-463-a-novel-approach-to-treating-ms-related-depression-with-dr-robert-motl-and-kelly/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/realtalk-ms-779631/episode-463-a-novel-approach-to-treating-ms-related-depression-with-dr-robert-motl-and-kelly.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Living with depression has been described as "like living under a wet, heavy blanket". It can stop someone from showing up at work, meeting up with friends, and even connecting with their family. One out of every two people living with MS will experience depression at some point in their MS journey. The METS for MS study is focused on a novel approach to treating major depressive disorder among people with MS -- one that doesn't require another infusion, injection, or pill. This week, Dr. Robert Motl, principal investigator for the METS for MS study, joins us to explain what the study is about and what his team is learning. And Kelly, who lives with progressive MS, joins us to share how her participation in the study became life-changing. We'll also tell you about the $500,000 donation to MS research that Fernando Mendoza and his family just made. We're sharing the details about the CAR-NKT cell therapy for MS that's being developed at UCLA. You'll learn about the novel nanoparticle therapy for MS that's being developed by a team at Syracuse University's BioInspired Institute. And we're sharing the surprising results of a study that measured the effectiveness of Rituximab versus Ocrevus. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A study focusing on a novel approach to treating MS-related depression :22 Fernando Mendoza and his family donate $500,000 to MS research 1:18 UCLA research team receives a $7.49 million dollar grant to develop CAR-NKT therapy for MS 2:22 Syracuse University research team receives NIH grant to develop novel nanoparticle therapy for MS 6:22 Study results: Rituximab and Ocrevus were compared head-to-head and the results are surprising 9:43 Dr. Robert Motl explains the Mood and Exercise Training Study for Multiple Sc…